Kidney and haemostasis

K. Andrassy

doi:10.5482/HAMO-14-08-0032

Hämostaseologie, Table of Contents

Hamostaseologie 2015; 35(01): 73-76
DOI: 10.5482/HAMO-14-08-0032

Review

Schattauer GmbH

Kidney and haemostasis

A (personal) time-journeyNiere und HämostaseEine (persönliche) Zeitreise

Authors

K. Andrassy

¹Med Universitätsklinik – Nephrologie, Heidelberg, Germany

Abstract

Summary

Renal insufficiency is characterized by thrombocytopathy, caused by the accumulation of water soluble and protein bound waste products of protein metabolism, which are not adequately eliminated by the kidney. The kidneys also excrete drugs and their metabolites, which accumulate if dosages are not adjusted to the renal function and may cause clinically relevant bleeding (i. e. synthetic penicillins, vitamin K antagonists, new oral anticoagulants). Therefore, each patients kidney function (GFR) ought to be evaluated by the KDIGO guidelines. The survival of chronic renal patients is lowered by increasing cardiovascular complications. Particularly frequent is non-valvular atrial fibrillation. The recommended prophylaxis with vitamin K antagonists for renal insufficiency is hampered by increased bleeding as well as by augmented (coronary) vascular and valvular calcification. It is not known yet whether prophylaxis with vitamin K may prevent this complication. Conclusion: Because new oral anticoagulants are equally or even more effective and cause less bleeding, they may be favoured in future and even in end-stage renal failure if more is known about dosing, safety and efficacy. The measurement of serum FGF 23 concentration may be helpful as a marker for their use.

Zusammenfassung

Die Niereninsuffizienz ist durch eine Thrombozytopathie gekennzeichnet und wird durch Kumulation von Abbauprodukten aus dem Eiweißstoffwechsel hervorgerufen. Die Niere ist aber auch Ausscheidungsorgan für Medikamente und ihre Metabolite. Ohne Dosisanpassung kumulieren sie bei eingeschränkter Nierenfunktion und können Blutungen hervorrufen (z. B. synthetische Penicilline, Vitamin-K-Antagonisten, neue orale Antikoagulanzien). Daher ist bei jedem Patienten die Nierenfunktion nach den KDIGO-Richtlinien zu ermitteln. Das Überleben des chronisch Nierenkranken ist durch gesteigerte kardiovaskuläre Komplikationen limitiert. Vor allem Vorhofflimmern ist gegenüber dem Nierengesunden gehäuft. Die empfohlenen Vitamin K-Antagonisten führen bei Niereninsuffizienz zu vermehrten Blutungen und zu gesteigerter (koronarer) Gefäßund Herzklappenverkalkung. In wie weit die Substitution mit Vitamin K diese Verkalkung vermindern kann, wird zurzeit geprüft. Schlussfolgerung: Nachdem die neuen oralen Antikoagulanzien bei gleicher oder besserer Wirkung die Blutungsgefährdung in der Niereninsuffizienz reduzieren, könnten sie in Zukunft nach Dosisanpassung und Ausschluss unerwünschter Arzneimittelwirkungen möglicherweise gegenüber den Vitamin-K-Antagonisten bevorzugt werden. Als Marker für ihren Einsatz könnte die FGF-23-Serumkonzentration dienen.

Keywords

Uremic bleeding - FGF 23 - vitamin K antagonists - myocardial infarction

Schlüsselwörter

Urämie - Blutung - FGF 23 - Vitamin-K-Antagonisten - Myokardinfarkt

Full Text

References

References
1 Blumberg BS, Alter HJ, Visnich S. A “new “antigen in leukemia sera. J Amer Ass 1965; 191: 541-546.
2 Krugman S. Viral hepatitis: overview and historical perspectives. Yale J Biol Med 1976; 49: 199-203.
3 Andrassy K, Ritz E, Sanwald R. Australia-Antigen-Nachweis in Fibrinogenkonzentraten und anderen gerinnungsaktiven Proteinen. Dtsch Med Wschr 1970; 95: 2467-2469.
4 Kuo G, Choo QL, Alter HJ. et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362-364.
5 Rath CE, Maillard JA, Schreiner GE. Bleeding tendency in uremia. New Engl J Med 1957; 257: 808-811.
6 Vanholder R, DeSmet R, Glorieux G. et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943.
7 Weiner DE, Tighiouart H, Amin MG. et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15: 1307-1315.
8 Meijers BKI, Bammens B, De Moor B. et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008; 73: 1174-1180.
9 Noris M, Benigni A, Boccardo P. et al. Enhanced nitric oxide synthesis in uremia: implications for platelet dysfunction and dialysis hypotension. Kidney Int 1993; 44: 445-450.
10 Sloand EM, Sloand JA, Prodouz K. et al. Reduction of platelet glycoprotein Ib in uraemia. Brit J Haematol 1991; 77: 375-381.
11 Gawaz MP, Dobos G, Späth M. et al. Impaired function of platelet membrane glycoprotein IIbIIIa in end-stage renal disease. J Am Soc Nephrol 1994; 05: 36-46.
12 Boccardo P, Remuzzi G. Coagulation problems in dialysis patients. In: Lameire N, Mehta RL. (eds). Complications of Dialysis. New York: Marcel Dekker; 2000: 327-341.
13 Andrassy K, Ritz E, Hasper M. et al. Penicillin-induced coagulation disorder. Lancet 1974; ii: 1039-1041.
14 Andrassy K, Weischedel E, Ritz E. et al. Bleeding in uremic patients after carbenicillin. Thromb Haemost 1976; 36: 115-126.
15 Spannagel M, Bauersachs R, Debus ES. et al. Therapie mit Dabigatran. Hämostaseologie 2012; 32: 294-305.
16 Laux V, Perzborn A, Heitmeier S. et al. Direct inhibitors of coagulation proteins the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?. Thromb Hamost 2009; 102: 892-899.
17 Bucha E, Kreml R, Nowak G. In -vitro study of r-hirudin permeability through membranes of different haemodialysers. Nephrol Dial Transplant 1999; 14: 2922-2926.
18 Levey AS, Bosch JP, Lewis JB. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 13: 461-470.
19 Levey AS, Stevens LA, Schmid CH. et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
20 Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
21 Kidney Disease: Improving global outcomes (KDIGO) CKD Work group. KDIGO 2012 Clinical practice guidelines for the evaluation and management of chronic kidney disease. Kidney Int 2013; 03 (Suppl): 1-150.
22 Lindeman RD. Overview: renal physiology and pathophysiology of aging. Am J Kidney Dis 1990; 16: 275-282.
23 Vanholder R, Glorieux G, van Bliesen W. Advantages of new hemodialysis membranes and equipment. Nephron Clin Pract 2010; 114: c165-c172.
24 Eschbach JW, Egriev JC, Downing MR. et al. Correction of anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. New Engl J Med 1987; 316: 73-78.
25 Moia M, Mannucci PM, Vizzotto L. et al. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 1987; ii: 1227-1229.
26 Fusté B, Serradelli M, Escolar G. et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 2002; 88: 678-685.
27 Nauta ST, van Domburg RT, Nuis RJ. et al. Decline in 20-year mortality after myocardial infarction in patients with chronic kidney disease: evolution from the prethrombolysis to the percutaneous coronary intervention. Kidney Int 2013; 84: 355-358.
28 Alonso A, Lopez FL, Matsushita K. et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2011; 123: 2946-2953.
29 Olesen JB, Lip GY, Kamper AL. et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. New Engl J Med 2012; 36: 625-635.
30 Herzog CA, Asinger RW, Berger AK. Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease improving global outcomes (KDIGO). Kidney Int 2011; 80: 572-586.
31 Hart G, Benavente O, McBride R. et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.
32 Reinecke H, Brand E, Mesters R. et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20: 705-711.
33 Lega JC, Bertoletti L, Gremillet C. et al. Consistency of safety profile of new anticoagulants in patients with renal failure. J Thromb Haemost 2014; 12: 337-343.
34 Hohnloser SH, Hijazi Z, Thomas L. et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Europ Heart J 2012; 33: 2812-2830.
35 Koos R, Mahnken AH, Mühlenbruck G. et al. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computer tomography. Am J Cardiol 2005; 96: 747-749.
36 Schurgers LJ, Joosen IA, Laufer EM. et al. Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype. PLoS One 2012; 07: 1-14.
37 Krueger T, Westenfeld R, Ketteler M. et al. Vitamin K deficiency in CKD patients: a modifiable risk factor for vascular calcification?. Kidney Int 2009; 76: 18-22.
38 Cannata-Andia JB, Fernandez-Martin JL, Locatelli F. et al. Use of phosphatebinding agents is associated with a lower risk of mortality. Kidney Int 2013; 84: 998-1008.
39 Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012; 82: 737-747.
40 Faul C, Amaral AP, Oskouel B. et al. FGF 23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408.
41 Seiler S, Reichart B, Roth D. et al. FGF – 23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010; 25: 3983-3989.
42 Arnlöv J, Carlsson AC, Sundström J. et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 2012; 83: 160-166.
43 Isakova T, Wahl p, Vargas GS. et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378.
44 Shearer MJ, Bechtold H, Andrassy K. et al. Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status. J Clin Pharmacol 1988; 28: 88-95.
45 Schurgers LJ. Vitamin K: key vitamin in controlling vascular calcification. Kidney Int 2012; 83: 782-784.
46 Westenfeld R, Krueger T, Schlieper G. et al. Effect of Vitamin K2 supplementation on functional Vitamin K deficiency in haemodialysis patients: a randomized trial. Am J Kidney Dis 2012; 59: 186-195.